Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma

OncoImmunology

Volumn 3, Issue 2, 2014, Pages

  Lowe, Devin B ^a   Bose, Anamika ^a   Taylor, Jennifer L ^a   Tawbi, Hussein ^a,b   Lin, Yan ^a,b   Kirkwood, John M ^a,b   Storkus, Walter J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Dasatinib; Dendritic cell; Melanoma; Myeloid derived suppressor cells; Tregs; Vaccine

Indexed keywords

CD11B ANTIGEN; CHEMOKINE RECEPTOR CXCR3; DASATINIB; DENDRITIC CELL VACCINE; GLYCOPROTEIN P 15095; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; HYPOXEMIA; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; SURVIVAL TIME; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84899073185     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27589     Document Type: Article

References (50)

1. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol 2012; 795:1-34; PMID:21960212; http://dx.doi. org/10.1007/978-1-61779-337-0_1.
2. Natarajan N, Telang S, Miller D, Chesney J. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs 2011; 71:1233-50; PMID:21770473; http://dx.doi. org/10.2165/11591380-000000000-00000.
3. Montero JC, Seoane S, Ocaña A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011; 17:5546-52; PMID:21670084; http://dx.doi.org/10.1158/1078-0432.CCR-10-2616.
4. Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist 2011; 16:566-78; PMID:21521831; http://dx.doi.org/10.1634/theoncologist.2010-0408.
5. Kim LC, Rix U, Haura EB. Dasatinib in solid tumors. Expert Opin Investig Drugs 2010; 19:415-25; PMID:20113198; http://dx.doi. org/10.1517/13543781003592097.
6. Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti C, Subramanian S, Devasahayam N, Munasinghe JP, Mitchell JB, et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 2011; 71:6350-9; PMID:21878530; http://dx.doi. org/10.1158/0008-5472.CAN-11-2025.
7. Tailor TD, Hanna G, Yarmolenko PS, Dreher MR, Betof AS, Nixon AB, Spasojevic I, Dewhirst MW. Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther 2010; 9:1798-808; PMID:20515941; http://dx.doi. org/10.1158/1535-7163.MCT-09-0856.
8. Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, McKenna WG, Bernhard EJ. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009; 69:6347-54; PMID:19622766; http://dx.doi.org/10.1158/0008-5472.CAN-09-0657.
9. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; http://dx.doi.org/10.1158/1078-0432.CCR-08-1332.
10. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011; 77:12-9; PMID:20304669; http://dx.doi. org/10.1016/j.critrevonc.2010.02.004.
11. Bose A, Lowe DB, Rao A, Storkus WJ. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 2012; 22:236-43; PMID:22504156; http://dx.doi. org/10.1097/CMR.0b013e3283538293.
12. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH, Storkus WJ. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 2011; 129:2158-70; PMID:21170961; http://dx.doi.org/10.1002/ijc.25863.
13. Pan PY, Wang GX, Yin B, Ozao J, Ku T, Divino CM, Chen SH. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008; 111:219-28; PMID:17885078; http://dx.doi.org/10.1182/blood-2007-04-086835.
14. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69:2514-22; PMID:19276342; http://dx.doi.org/10.1158/0008-5472.CAN-08-4709.
15. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69:2506-13; PMID:19244102; http://dx.doi.org/10.1158/0008-5472.CAN-08-4323.
16. Coluccia AM, Cirulli T, Neri P, Mangieri D, Colanardi MC, Gnoni A, Di Renzo N, Dammacco F, Tassone P, Ribatti D, et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008; 112:1346-56; PMID:18524994; http://dx.doi. org/10.1182/blood-2007-10-116590.
17. Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A, Sznol M. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011; 117:2202-8; PMID:21523734; http://dx.doi.org/10.1002/cncr.25766.
18. Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, et al. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer 2012; 106:85-91; PMID:22127285; http://dx.doi.org/10.1038/bjc.2011.514.
19. Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia 2010; 24:896-900; PMID:20147973; http://dx.doi. org/10.1038/leu.2010.11.
20. Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008; 14:2484-91; PMID:18413841; http://dx.doi.org/10.1158/1078-0432.CCR-07-4393.
21. Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood 2012; 120:4533-43; PMID:22936666; http://dx.doi.org/10.1182/blood-2012-02-407163.
22. Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85:387-98; PMID:20662899; http://dx.doi.org/10.1111/j.1600-0609.2010.01501.x.
23. Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, Lahesmaa-Korpinen AM, Hautaniemi S, Bouchet S, Molimard M, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 2013; 27:914-24; PMID:23192016; http://dx.doi.org/10.1038/leu.2012.348.
24. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23:1398-405; PMID:19295545; http://dx.doi.org/10.1038/leu.2009.46.
25. + regulatory T cells. Br J Haematol 2009; 144:195-205; PMID:19016717; http://dx.doi. org/10.1111/j.1365-2141.2008.07433.x.
26. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med 2008; 205:2125-38; PMID:18725522; http://dx.doi.org/10.1084/jem.20080099.
27. Yan M, Jene N, Byrne D, Millar EK, O'Toole SA, McNeil CM, Bates GJ, Harris AL, Banham AH, Sutherland RL, et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basallike breast cancers. Breast Cancer Res 2011; 13:R47; PMID:21521526; http://dx.doi.org/10.1186/bcr2869.
28. 2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011; 71:7463-70; PMID:22025564; http://dx.doi.org/10.1158/0008-5472.CAN-11-2449.
29. Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, Whitton JL, Overwijk WW, Restifo NP, Reisfeld RA. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A 2000; 97:5492-7; PMID:10779556; http://dx.doi.org/10.1073/pnas.090097697.
30. Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med 2004; 2:40; PMID:15563374; http://dx.doi. org/10.1186/1479-5876-2-40.
31. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 2007; 13:4233-44; PMID:17634553; http://dx.doi.org/10.1158/1078-0432.CCR-06-2981.
32. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, Deng J, Forman S, Figlin R, Yu H. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 2010; 70:9599-610; PMID:21118964; http://dx.doi.org/10.1158/0008-5472.CAN-10-1293.
33. Cohen PA, Ko JS, Storkus WJ, Spencer CD, Bradley JM, Gorman JE, McCurry DB, Zorro-Manrique S, Dominguez AL, Pathangey LB, et al. Myeloid-derived suppressor cells adhere to physiologic STAT3-vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape. Immunol Invest 2012; 41:680-710; PMID:23017141; http://dx.doi.org/10.3109/08 820139.2012.703745.
34. Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, Mami-Chouaib F, Chouaib S. Hypoxiainducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 2012; 72:4629-41; PMID:22962263; http://dx.doi. org/10.1158/0008-5472.CAN-12-1383.
35. Hasmim M, Noman MZ, Lauriol J, Benlalam H, Mallavialle A, Rosselli F, Mami-Chouaib F, Alcaide-Loridan C, Chouaib S. Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells. J Immunol 2011; 187:4031-9; PMID:21911602; http://dx.doi.org/10.4049/jimmunol.1101011.
36. Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, Buart S, Berchem G, Romero P, Mami-Chouaib F, et al. Blocking hypoxiainduced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res 2011; 71:5976-86; PMID:21810913; http://dx.doi. org/10.1158/0008-5472.CAN-11-1094.
37. Noman MZ, Buart S, Van Pelt J, Richon C, Hasmim M, Leleu N, Suchorska WM, Jalil A, Lecluse Y, El Hage F, et al. The cooperative induction of hypoxiainducible factor-1 α and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009; 182:3510-21; PMID:19265129; http://dx.doi.org/10.4049/jimmunol.0800854.
38. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008; 14:5947-52; PMID:18829471; http://dx.doi.org/10.1158/1078-0432.CCR-08-0229.
39. van der Bruggen P, Van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 2006; 18:98-104; PMID:16343880; http://dx.doi.org/10.1016/j. coi.2005.11.013.
40. Zhao X, Bose A, Komita H, Taylor JL, Kawabe M, Chi N, Spokas L, Lowe DB, Goldbach C, Alber S, et al. Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumorassociated stromal antigens. Mol Ther 2011; 19:805-14; PMID:21189473; http://dx.doi.org/10.1038/mt.2010.295.
41. Wölfl M, Schwinn S, Yoo YE, Reß ML, Braun M, Chopra M, Schreiber SC, Ayala VI, Ohlen C, Eyrich M, et al. Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis. Blood 2013; 122:1203-13; PMID:23836556; http://dx.doi.org/10.1182/blood-2013-03-488072.
42. Seliger B, Ritz U, Abele R, Bock M, Tampé R, Sutter G, Drexler I, Huber C, Ferrone S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001; 61:8647-50; PMID:11751378.
43. rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two selfantigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999; 162:989-94; PMID:9916724.
44. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi. org/10.1038/nrc3239.
45. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690.
46. Shimokaze T, Mitsui T, Takeda H, Kawakami T, Arai T, Ito M, Iwaba A, Izumino H, Takahashi N, Kanno M, et al. Severe hemorrhagic colitis caused by dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatr Hematol Oncol 2009; 26:448-53; PMID:19657995.
47. Erkut M, Erkut N, Ersoz S, Arslan M, Sonmez M. A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use. Acta Haematol 2010; 123:205-6; PMID:20375493; http://dx.doi.org/10.1159/000306070.
48. Breccia M, Alimena G. Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients. BioDrugs 2011; 25:147-57; PMID:21528941; http://dx.doi.org/10.2165/11591840-000000000-00000.
49. Tinsley SM. Safety profiles of second-line tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. J Clin Nurs 2010; 19:1207-18; PMID:20345830; http://dx.doi. org/10.1111/j.1365-2702.2009.03167.x.
50. Kim LC, Rix U, Haura EB. Dasatinib in solid tumors. Expert Opin Investig Drugs 2010; 19:415-25; PMID:20113198; http://dx.doi. org/10.1517/13543781003592097.